[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"high-grade-glioma-who-iii-iv\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:high-grade-glioma-who-iii-iv":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,77,105],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100639888","phase-2-fg001-near-infrared-fluorescence-imaging-during-tumor-resection-in-newly-diagnosed-high-grade-glioma-100639888",false,"NCT07609472","FG001 Near-Infrared Fluorescence Imaging During Tumor Resection in Newly Diagnosed High-Grade Glioma","Prospective, Single Group, Open-label Multicenter Phase 2 Study With Single-dose Administration of the Optical Imaging Agent FG001 in Subjects With Newly Diagnosed High Grade Glioma Scheduled for Neurosurgical Tumor Resection Under NIR Fluorescence Guidance","Inclusion Criteria:\n\n1. Age 18 and older\n2. Radiological evidence of a unifocal, contrast-enhancing brain lesion consistent with HGG, characterized by ring-enhancing or heterogeneously enhancing tumor with central hypointensity suggestive of necrosis, based on preoperative contrast-enhanced T1-weighted MRI.\n3. Suspected HGG based on imaging, later confirmed as WHO Grade 3 or 4 glioma postsurgery. Eligible histologies (WHO CNS5) upon intraoperative or postoperative confirmation are:\n\n   * Glioblastoma, IDH-wildtype (CNS WHO Grade 4)\n   * Astrocytoma, IDH-mutant (CNS WHO Grade 3 or 4)\n   * Oligodendroglioma, IDH-mutant, 1p\u002F19q-codeleted (CNS WHO Grade 3)\n   * Ependymoma (CNS WHO Grade 3)\n4. No prior tumor-specific treatment, including surgery, chemotherapy, radiotherapy, or investigational therapy (i.e., newly diagnosed, treatment-naïve HGG).\n5. Subject is scheduled to undergo first neurosurgical intervention with the intent of GTR of the contrast-enhancing lesion.\n6. Surgery must be clinically anticipated to allow GTR, defined as removal of ≥98% of contrast-enhancing tumor, based on neurosurgeon assessment and preoperative imaging.\n7. Indication for surgical tumor resection. The anatomical location of the contrast agent-accumulating tumor allows the possibility of complete resection. Resectability and EOR will be retrospectively assessed by an independent blinded centralized review of preoperative and postoperative MRI.\n8. KPS ≥70, as assessed within 14 days prior to study treatment. Subject must not previously have received the trial drug (FG001).\n9. Male subjects must commit to use barrier contraception (e.g., condom) during the trial and for 30 days after the end-of-trial visit and avoid sperm donation during this period.\n10. Women of childbearing potential must agree to use highly effective method of contraception during the trial and for 30 days after the end-of-trial visit. Acceptable methods of contraception include intrauterine device or hormonal contraception (oral contraceptive pill, depot injections or implant, transdermal depot patch or vaginal ring). To be considered sterilized or infertile, females must have undergone surgical sterilization (bilateral tubectomy, hysterectomy or bilateral ovariectomy) or be post-menopausal (defined as at least 12 months amenorrhea; may be confirmed with FSH test if there is doubt).\n11. Subject is capable of understanding and giving written informed consent\n\nExclusion Criteria:\n\n1. Tumor location in the midline, basal ganglia, cerebellum, or brainstem where resection is not safely achievable or is considered high-risk.\n2. Tumors judged by the PI to infiltrate critical motor pathways.\n3. Multifocal disease, defined as:\n\n3a. More than one contrast-enhancing lesion; or 3b. Additional contrast-enhancing lesions unrelated to the primary tumor; or 3c. Evidence of extracerebral metastases\n\n4\\. Substantial non-contrast-enhancing tumor areas suggestive of low-grade glioma with malignant transformation, as assessed by preoperative MRI. Defined as ≥50% of non-CE volume in relation to CE tumor volume.\n\n5\\. Tumor location is not amenable to GTR based on neuro-surgeon assessment.\n\n6\\. Application of iMRI or intraoperative ultrasound guidance during surgical resection is prohibited to avoid bias in resection outcome measurement.\n\n7\\. Medical contraindications to MRI (e.g., pacemaker).\n\n8\\. Any known allergy or hypersensitivity to: 8a. ICG or any component of the IP 8b. Gadolinium-based contrast agents\n\n9\\. Pre-existing severe chronic renal impairment, defined as: 9a. Estimated indexed and non-indexed glomerular filtration rate (eGFR ≤30 mL\u002Fmin\u002F1.73 m² AND (eGFR ≤30 mL\u002Fmin) 9b. Assessed within 30 days prior to enrollment\n\n10\\. Pre-existing hepatic insufficiency, defined as: 10a. AST and alanine transaminase ALT \\>3 times the upper limit of normal; or 10b. Total bilirubin \\>1.5 times the upper limit of normal unless the elevation is attributable to Gilbert's syndrome.\n\n10c. Assessed within 30 days prior to enrollment\n\n11\\. Abnormal coagulation profile, defined as any: 11a. Platelets \\\u003C 100,000 11b. aPTT \\>1.5x upper limit of normal, or 11c. INR \\> 1.7 11d. Assessed within 30 days prior to enrollment\n\n12\\. QTc will be assessed using Fridericia's correction (QTcF); thresholds for exclusion is \\> 470 ms or subjects with QTcF \\> 470 ms will be excluded.\n\n13\\. History of malignant tumor in any body site (excluding adequately treated basal cell carcinoma of the skin).\n\n14\\. Unwilling or unable to follow the protocol requirements.\n\n15\\. Prior history of serious gastrointestinal perforation, diverticulitis, and\u002For peptic ulcer disease.\n\n16\\. Existing or planned pregnancy or lactation, or unwillingness\u002Finability to use effective contraception during the study.\n\n17\\. Inability to provide informed consent due to significant language barrier, cognitive impairment, or dysphasia.\n\n18\\. Simultaneous participation in another interventional clinical trial or trial participation in any other clinical study 30 days prior to enrollment.\n\n19\\. Subjects enrolled that are later determined to have non-high-grade gliomas will be considered a screen failure (e.g., Excluded Population), including but not limited to: 19a. IDH-mutant oligodendroglioma, or astrocytoma 19b. Metastasis 19c. Lymphoma","ALL","18 Years",{"count":19,"type":20},76,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This clinical trial aims to determine if FG001 can assist surgeons in identifying the difference between tumor and healthy tissue during surgery in participants with newly diagnosed high-grade glioma. The scheduled neurosurgical tumor resection will occur under NIR fluorescence guidance and support the surgeons in achieving complete removal of the cancer.\n\nFG001 is a 'fluorescent imaging agent,' which is a dye that glows under a special light to help doctors see certain tissues.\n\nThe main questions it aims to answer are:\n\n1. To see how well a special light (called NIR fluorescence imaging) can show the difference between the tumor and the nearby healthy tissue during surgery. This difference is measured by comparing how bright the tumor looks to how bright the normal tissue looks.\n2. Another goal is to find out how many patients have almost all the tumor removed. This is checked by looking at MRI scans, taken within 48 hours after surgery, to see if the leftover tumor is smaller than 0.175 cubic centimeters.\n\nParticipants will receive FG001 before tumor resection surgery and will participate in follow-up visits during the six months after surgery. Follow-up visits may include brain MRI, bloodwork, physical assessments, vital signs, assessment of functional and neurologic status, quality-of-life assessments, adverse event monitoring, and review of concomitant medications.",[26],"High-Grade Glioma (WHO III-IV)",[28,29],"glioma","brain tumor resection","NOT_YET_RECRUITING","2026-05-27",{"date":33,"type":34},"2026-05-29","ACTUAL",{"date":36,"type":20},"2026-06-30",{"date":38,"type":20},"2028-07-31",{"name":40,"class":41},"FluoGuide A\u002FS","INDUSTRY",5,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100630521","local-targeted-therapy-with-alpha-emitter-225acac-dota-sp-tat-in-newly-diagnosed-glioma-who-g3-g4-100630521","NCT07488754","Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) In Newly Diagnosed Glioma (WHO G3-G4)","Medical Experiment - Assessment of Efficacy & Safety of Local, Targeted Therapy With Neuropeptide Labelled With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) as Supplementary Therapy Following Standard Treatment Of Glioma (WHO G3-G4)","Inclusion Criteria:\n\n* age 18-80;\n* histologically confirmed diffuse glioma (CNS WHO G3-G4);\n* after standard treatment with biopsy or resection, radiotherapy and\u002For chemotherapy;\n* no sign of progression or radiation necrosis;\n* functional state \\>70 according to Karnofsky's performance scale (KPS);\n* ability to give informed consent to participate in the study.\n\nExclusion Criteria:\n\n* low-grade glioma;\n* progression or recurrence defined as: deterioration of the patient's condition according to the Karnofsky Performance Scale, worsening of neurological function, progressive neurological deficit, need to initiate or increase corticosteroid dose by \\>50%, progression or recurrence assessed on MRI (RANO criteria);\n* radiation-induced necrosis secondary to radiotherapy; may occur within the first 3 months after radiotherapy (exception: a patient after resection of radiation necrosis - not earlier than 4 weeks post-surgery, after a follow-up MRI);\n* need for emergency surgery (e.g., acute increase in intracranial pressure);\n* significant postoperative complications, e.g., KPS \\\u003C 70, wound infection, cerebrospinal fluid leak;\n* leak into the ventricular system \\>10% during the catheter patency check;\n* open\u002Fventricle-connected resection cavity;\n* catheter obstruction;\n* estimated life expectancy under 3 months;\n* patients without preserved logical\u002Fverbal contact;\n* lack of cooperation from the patient;\n* inability to give informed, voluntary consent to participate in the study;\n* patients enrolled in another medical trial;\n* patients who received any other investigational drug within 1 month prior to the first dose;\n* prior treatment with \\[225Ac\\]Ac-DOTA-SP;\n* breastfeeding or pregnant women;\n* severe comorbid organ diseases that, in the Investigator's opinion, significantly increase the procedural risk.","80 Years",{"count":52,"type":20},35,[54],"NA","Brain tumors account for 1.35% of all cancers and cause 2.2% of cancer-related deaths. Gliomas are the most common type, comprising 40-90% of central nervous system tumors in different age groups. The incidence of malignant gliomas is approximately 0.5-2 per 100,000 people annually. Standard treatments include surgical resection, radiotherapy, and chemotherapy, yet overall survival remains low, typically 1-3 years post-diagnosis. The study highlights the pressing need for novel treatment strategies, particularly given the infiltrative nature of gliomas and the potential for targeted therapies using neuropeptides.The aim of this study is to assess the efficacy and safety of local targeted therapy with \\[225Ac\\]Ac-DOTA-SP in newly diagnosed glioblastoma following standard treatment.It is an interventional study without a control group, initiated by the researcher. Patients included are aged 18-80 with WHO G3-G4 glioma post-first-line treatment, not requiring immediate surgery and meeting specific MRI criteria.Patients will receive a maximum of six cycles of \\[225Ac\\]Ac-DOTA-SP, involving pre-treatment assessments, local administration of the agent after ensuring catheter patency, and continuous monitoring. Blood tests and neurological evaluations will be performed regularly.Outcome will be assessed by measuring overall survival (OS) and progression-free survival (PFS). The study anticipates improvements in both OS and PFS when compared to current treatments, contributing to critical insights into targeted alpha therapy's effectiveness in glioblastoma.Treatment with \\[225Ac\\]Ac-DOTA-SP previously indicated few significant side effects, primarily transient issues like seizures. Patients will be closely monitored throughout the study to identify any adverse effects promptly.The estimated study duration is three years, with biological material collected for histopathological and genetic analysis during surgical reoperation.Data will be anonymized to protect patient confidentiality, stored securely, and made available only for the scope of the study.Led by Prof. Przemysław Kunert, the research team includes multiple co-investigators from neurosurgery and nuclear medicine departments.",[57,26,58],"Glioblastoma","Glioblastoma (GBM)",[60,61,62,63,64],"alpha emitter","glioblastoma","local therapy","225-Ac","high-grade glioma","RECRUITING","2026-03-30",{"date":68,"type":34},"2026-04-06",{"date":70,"type":34},"2025-10-01",{"date":72,"type":20},"2028-09",{"name":74,"class":75},"Medical University of Warsaw","OTHER",2,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":21,"phases":88,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":104},"100622873","phase-1-combination-adi-peg-20-tmz-and-rt-for-treatment-of-newly-diagnosed-high-grade-glioma-hgg-100622873","NCT07389278","Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)","A Phase 1\u002F2 Study of Pegylated Arginine Deiminase (ADI-PEG 20) Plus Radiotherapy (RT) and Temozolomide (TMZ) in Children, Adolescents, and Young Adults With Newly Diagnosed High-grade Glioma (HGG)","Inclusion Criteria:\n\n1. Participants must have histologically and molecularly confirmed newly diagnosed World Health Organization (WHO) grade 3 or 4 glioma.\n\n   1. Phase 1: any newly diagnosed HGG (including DMG of any location and primary spinal cord tumors).\n   2. Phase 2:\n\n      * Cohort 1: Newly diagnosed non-pontine, non-spinal cord HGG histone-wildtype.\n      * Cohort 2: Newly diagnosed non-pontine, non-spinal cord H3K27 altered diffuse midline glioma (DMG).\n      * Cohort 3: Newly diagnosed non-pontine, non-spinal cord H3G34 mutant diffuse hemispheric glioma (DHG).\n2. Prior surgery: must have undergone maximal safe resection. For patients with DMG of the pons, biopsy is sufficient.\n3. Prior Therapy: Participants must NOT have received ANY prior therapy (except surgery) before enrollment on study.\n4. Tumor Tissue Requirement: Participants must have sufficient tumor tissue (5-10 unstained formalin-fixed paraffin-embedded (FFPE) slides or a tumor block) for study enrollment.\n5. Age:\n\n   Phase 1:\n\n   o 3 to \\\u003C18 years of age.\n\n   Phase 2:\n   * Cohort 1: 3 to 25 years of age.\n   * Cohorts 2 \\& 3: 3 to 39 years of age.\n6. Performance Score: Karnofsky \\>= 50 for participants \\> 16 years of age and Lansky \\>= 50 for participants \\\u003C=16 years of age. Participants who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.\n7. Corticosteroids: Participants who are receiving dexamethasone must be on a stable or decreasing dose for at least 1 week prior to registration.\n8. Organ Function Requirements:\n\n   1. Peripheral absolute neutrophil count (ANC) \\>= 1000\u002Fmm\\^3.\n   2. Platelet count \\>= 100,000\u002Fmm\\^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment).\n   3. Creatinine Clearance (CrCl) or estimated glomerular filtration rate (eGFR) with cutoff value of ≥ 60 mL\u002Fmin for renal function in participants with age ≥ 18 years. For participants \\\u003C 18 years old, estimate eGFR using the Schwartz equation. eGFR (mL\u002Fmin\u002F1.73 m\\^2) = (k × Height (cm)) \u002F Serum Creatinine (mg\u002FdL).\n   4. Total bilirubin \\\u003C= 1.5 x upper limit of normal (ULN) for age; in presence of Gilbert's syndrome, total bilirubin \\\u003C 3 x ULN or direct bilirubin \\\u003C 1.5 x ULN.\n   5. alanine aminotransferase (ALT) \\\u003C= 3 x ULN.\n   6. aspartate aminotransferase (AST) \\\u003C= 3 x ULN.\n   7. Participants with seizure disorder may be enrolled if well controlled. Participants on non-enzyme inducing anticonvulsants may be excluded pending interaction(s) with study drug.\n9. The effects of ADI-PEG 20 have been shown to be associated with embryofetal toxicity in rodents. For this reason and because chemotherapy used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and 4 months after completion of treatment. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n10. A legal parent\u002Fguardian or participant must be able to understand, and willing to sign, a written informed consent and assent document, as appropriate.\n11. Participants must enroll on PNOC COMP if PNOC COMP is open to accrual at the enrolling institution.\n\nExclusion Criteria:\n\n1. Participants who have received any systemic therapy or RT, including any investigational agents.\n2. History of allergic reactions attributed to compounds of similar chemical or biologic composition to ADI-PEG 20 such as pegylated compounds.\n3. Phase 2 cohorts: tumors with epicenter in pons or spinal cord\n4. Participants with metastatic or leptomeningeal disease. Multi-focal disease should be discussed with the study chairs,\n5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection that would interfere with the study.\n6. Women of childbearing potential must not be pregnant or breast-feeding.\n7. Human immunodeficiency virus (HIV)-positive participants will be ineligible if HIV therapy regimen has not been stable for at least 4 weeks or there is intent to change the regimen within 8 weeks following enrollment, or if they are severely immunocompromised.\n8. Corrected QT Interval (QTc) cutoff \\>480 ms.\n\nImportant note: The eligibility criteria listed above are interpreted literally and cannot be waived.","3 Years","39 Years",{"count":87,"type":20},97,[89,23],"PHASE1","This is an open label, intra-patient dose escalation, to evaluate ADI-PEG 20, in combination with Temozolomide (TMZ) and radiation therapy (RT) in children, adolescents and young adult patients with newly diagnosed high grade glioma (HGG).",[57,26,92,93,94],"High-grade Glioma","Diffuse Midline Glioma, H3 K27M-Mutant","Diffuse Hemispheric Glioma, H3G34 Mutant","2026-01-28",{"date":97,"type":34},"2026-02-05",{"date":99,"type":20},"2026-03-09",{"date":101,"type":20},"2035-06-30",{"name":103,"class":75},"Sabine Mueller, MD, PhD",1,{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":116,"conditions":117,"keywords":120,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":76},"100605556","evaluation-of-image-quality-and-safety-of-the-myveo-surgical-visualization-headset-during-standard-neurosurgical-and-reconstructive-procedures-using-compatible-microscopes-100605556","NCT07164053","Evaluation of Image Quality and Safety of the MyVeo Surgical Visualization Headset During Standard Neurosurgical and Reconstructive Procedures Using Compatible Microscopes.","Image Quality Evaluation of Surgical Visualization Headset (Leica MyVeo) During Standard of Care Procedure Per User Manual","IMED-MYVEO","Inclusion Criteria:\n\nCandidates for the IMED-MyVeo study protocol must be appropriate patients for the applicable indication of use and have to fulfil the following inclusion criteria to be eligible for the recruitment of the study.\n\n1. Participants must be 18 years of age or older at the time of signing the informed consent.\n2. The participant or their legal representative must understand the study and have voluntarily signed and dated the Informed Consent Form, which has been approved by the Sponsor and the Ethics Committee for this study.\n3. Diagnosed with condition requiring surgical intervention per user manual.\n\n   GLOW400 Specific Inclusion Criteria\n4. Participants must have a suspected high-grade glioma (WHO grade III-IV) as evidenced by preoperative imaging modalities, which requires surgical intervention.\n5. The active substance 5-aminolevulinic acid (5-ALA) fluorescence dye is administered according to the 5-ALA instructions for use.\n\n   GLOW800 Specific Inclusion Criteria\n6. Participants must have a condition requiring surgical intervention in the cerebral vascular area as well as during plastic and reconstructive surgery.\n7. The Indocyanine Green (ICG) cyanine dye is administered as a contrast agent per instructions for use.\n\nCandidates who meet any of the following exclusion criteria will not be eligible for recruitment in the study.\n\nExclusion Criteria:\n\n1. Any uncontrolled systemic condition that may adversely affect the surgical outcome.\n2. Individuals holding United States citizenship.\n\n   GLOW400 Specific Exclusion Criteria\n3. Known allergy to 5-ALA hydrochloride or protoporphyrin's.\n4. Patients with porphyria (a condition characterized by the inability to break down protoporphyrin).\n\n   GLOW800 Specific Exclusion Criteria\n5. Known allergy to Indocyanine Green (ICG) cyanine dye.\n6. Severe iodine-induced reactions to macromolecular iodine-containing compounds (e.g., iodinated contrast media, iodine-based antiseptics, or drugs like amiodarone), especially if the reaction involved anaphylaxis or respiratory compromise.",{"count":114,"type":20},32,"OBSERVATIONAL","This study looks at how well the MyVeo surgical visualization headset works during routine surgeries. MyVeo is a wearable device that helps surgeons see the surgical area in high detail, including blood flow and tissue fluorescence, without needing to look through a traditional microscope. The study will involve patients undergoing brain, spine, ENT, or reconstructive surgery, where MyVeo is used as part of the standard care. Surgeons will rate the image quality, comfort, and safety of using MyVeo. The goal is to confirm that MyVeo provides clear images and supports safe and effective surgery. No extra procedures or risks are added for patients.",[26,118,119],"Cerebral Vascular Conditions Requiring Surgical Intervention","Conditions Requiring Plastic and Reconstructive Surgery",[121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140],"Surgical Visualization Headset","MyVeo","ARveo8x Microscope","Image Quality Assessment","Fluorescence Imaging","White Light Imaging","Neurosurgery","High-Grade Glioma","WHO Grade III-IV Glioma","Indocyanine Green (ICG)","5-Aminolevulinic Acid (5-ALA)","GLOW400","GLOW800","Post-Market Clinical Follow-Up (PMCF)","Head-Mounted Display (HMD)","Stereoscopic 3D Imaging","Surgical Ergonomics","Surgical Workflow","Intraoperative Visualization","Digital Surgical Accessory","2025-11-19",{"date":143,"type":34},"2025-11-20",{"date":145,"type":20},"2025-12-25",{"date":147,"type":20},"2027-06-30",{"name":149,"class":41},"Leica Microsystems (Schweiz) AG"]